Sun Pharma’s Winning Formula: Precision Over Expansion
India’s largest drugmaker Sun Pharma has carved out its niche by focusing on unmet patient needs rather than chasing every new market segment, according to founder and executive chairman Dilip Shanghvi. Speaking at the IFQM Symposium, he stressed the company’s strategy of developing therapies with fewer side effects and improved delivery systems. With an annual R&D spend of $450 million, Sun Pharma’s portfolio spans dermatology, oncology, and ophthalmology. Its psoriasis drug Ilumya generated $681 million in FY25 sales, while new alopecia therapy Leqselvi is set to challenge Eli Lilly’s Olumiant with a higher-dosage regimen. Today, two-thirds of Sun Pharma’s revenue comes from international markets, underscoring its global shift since acquiring Ranbaxy for $4 billion in 2014 despite its troubled past. Shanghvi emphasized that setbacks never invalidate strategy: success lies in execution.
You May Interested In
High Quality β-Nicotinamide adenine dinucleotide CAS 53-84-9 NADwith ready stock and best price
$3/UNIT FOB
2026-10-18
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Trump Tariff "Boomerang": $2.5 Billion Polysilicon Factory Faces Shutdown Crisis
-
China’s Chemical Time Bomb Just Got a Legal Fuse: The New Law That Could Save Thousands of Lives
-
U.S. Strikes Three Iranian Tankers as “Tanker-for-Tanker” Escalation Raises Chemical Shipping Risk
-
Panama Canal Delays Deeper Draft Cut, but Transit Capacity Is Still Tightening
-
Hormuz Closes, Paint Feels It First: How a Barrel of Oil Rewrites the Cost of Every Barrel of Coatings
-
Saudi Energy Facilities Hit as Middle East Feedstock Risk Spreads Toward the Red Sea
-
China Methanol Futures Hit Limit-Up as More Than 60% of Middle East Capacity Remains Offline
-
“Fake Fame” in a Forgotten Dock: Chinese Authorities Bust $100,000 Counterfeit Building Materials Ring
-
Asian Paints Dives Deeper into the Desert: Unveils Second UAE Plant to Dominate GCC Coatings Market
-
From Rust to Recharge: Novonix Ignites America’s Graphite Independence with Twin Mega-Plants in Chattanooga
Recommend Reading
-
![September 1: Chemical Price Hikes Take Effect Across the Board]()
September 1: Chemical Price Hikes Take Effect Across the Board
-
![Vertex Buys Crinetics for $10 Billion: Rare Disease M&A Is Back]()
Vertex Buys Crinetics for $10 Billion: Rare Disease M&A Is Back
-
![Nestlé Drops Artificial Colors Worldwide by 2026: Food Additives Face a Reformulation Shock]()
Nestlé Drops Artificial Colors Worldwide by 2026: Food Additives Face a Reformulation Shock
-
![The “Counter-Wind Ledger” of CHF 11.2 Billion: Sika Barely Grew in 2025—Yet Kept Taking Market Share]()
The “Counter-Wind Ledger” of CHF 11.2 Billion: Sika Barely Grew in 2025—Yet Kept Taking Market Share
-
![South Korea to Impose Anti-Dumping Duties on Caustic Soda: Chinese Mainland Firms Face Up to 22.21%, Taiwan Region 38.89%]()
South Korea to Impose Anti-Dumping Duties on Caustic Soda: Chinese Mainland Firms Face Up to 22.21%, Taiwan Region 38.89%
-
![Business Society’s Market Outlook for Soda Ash on August 27, 2026: Clearly Downward]()
Business Society’s Market Outlook for Soda Ash on August 27, 2026: Clearly Downward
-
![Market Conditions Continue to Weaken; Melamine Remains in a Low Range]()
Market Conditions Continue to Weaken; Melamine Remains in a Low Range
-
![The Game Between Supply and Demand Tends Toward Equilibrium; Formic Acid Ranges Sideways]()
The Game Between Supply and Demand Tends Toward Equilibrium; Formic Acid Ranges Sideways
-
![This week, the market trend for maleic anhydride in China is mainly weak consolidation]()
This week, the market trend for maleic anhydride in China is mainly weak consolidation
-
![Business Society’s Market Outlook for Gasoline on August 26, 2026: Relatively Strong Consolidation]()
Business Society’s Market Outlook for Gasoline on August 26, 2026: Relatively Strong Consolidation
